Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 358.50
Bid: 358.50
Ask: 384.50
Change: -27.50 (-7.12%)
Spread: 26.00 (7.252%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 386.00
CHG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Covid-19 Update

14 Apr 2020 07:00

RNS Number : 4627J
Chemring Group PLC
14 April 2020
 

 

FOR IMMEDIATE RELEASE 14 April 2020

CHEMRING GROUP PLC ("Chemring" or the "Group")

COVID-19 Update

Chemring today provides the following update in response to the COVID-19 ("CV-19") global pandemic.

People

Our priority is the health, safety and well-being of our people, their families, our customers and the communities in which we operate. We continue to focus on risk mitigation and business continuity, and are implementing the latest government and health authority recommendations in each of our home markets.

Our people have risen to the challenge, adapting their working practices to minimise the spread of the virus, whilst continuing to focus on the critical needs of our customers.

Operations

In the US, the UK and Norway, Chemring's operations have been designated as critical to the defence and national security industrial base, and in Australia the risk of business interruption is considered to be low. All our businesses remain open, with business continuity plans mobilised at every location. We continue to make every effort to maintain delivery of essential services and manufacturing production in support of our customers.

Customers

We are proud of the essential contribution that Chemring makes to the ongoing defence and national security missions of our customers and we are committed to supporting them throughout this crisis.

As disclosed in our trading update on 4 March 2020, the Group has a strong order book with order cover for the 2020 financial year of almost 90% at that time. Since that announcement order placement has continued including the recent receipt of a $17m order to supply countermeasures for the F-35 Joint Strike Fighter programme; work under this contract will be carried out at our facilities in Tennessee and Australia.

Our manufacturing businesses continue to work closely with their customer representatives to deliver timely testing and acceptance of products. To date we have worked through some CV-19 related disruptions where customer representatives have not been able to complete product acceptance procedures on a timely basis and going forward this presents a risk of some short term revenue deferrals. Our wide geographic and customer base provides some mitigation to this potential short-term risk.

Financial position and mitigating actions

The Group has committed revolving credit facilities ("RCF") totaling approximately £150m. These facilities mature in October 2022, with a two-year extension option. The Group's current level of net debt is approximately £84m, comprising current cash balances of c.£33m and drawings under the RCF of £108m. In total the Group therefore has available liquidity of approximately £73m.

The financial covenants associated with the RCF are Net debt : EBITDA of less than 3.0x and Net interest cover greater than 4.0x. At the last measurement date of 31 January 2020, the actual covenants were 1.18x and 15.6x.

Given the uncertainty surrounding the length of the CV-19 pandemic, the Group has taken various actions to protect profitability and to conserve cash. Operational expenditure has been reduced and all discretionary spending is tightly controlled as we seek to ensure the Group is well placed to navigate the current challenges. The already established enhanced focus on working capital management, in particular the reduction of intra-period net debt volatility, is proving beneficial and the Group is focusing on ensuring working capital disciplines are maintained in these challenging times.

Dividend

The Group's FY19 final dividend of 2.4p (£6.7m) was approved by shareholders at the Annual General Meeting on 4 March 2020. The dividend will be paid on 24 April 2020 to those shareholders who were on the register on 3 April 2020.

Outlook and guidance

The duration and impact of CV-19 across our home markets is at this stage unknown, and we are clearly working in a changing and more challenging environment. We will continue to work closely with our customers and other stakeholders, and will provide further updates as appropriate.

In the longer term, Chemring is well placed, with a robust strategy, market-leading positions across different geographies and sectors, and with products and services that are critical to our government and blue-chip customers. This, together with the Group's strong balance sheet, gives the Board confidence that despite the near-term uncertainty, Chemring's long-term prospects remain strong.

Michael Ord, Group Chief Executive, commented:

"These are clearly unprecedented times in which our number one priority is the health, safety and well-being of our people, their families, our customers and the communities in which we operate. All of our businesses remain open reflecting our essential contribution to the defence and national security missions of our customers and we are committed to supporting them throughout this crisis. Whilst we are clearly mindful of market uncertainty due to COVID-19, we continue to see positive momentum across the Group and our improving order book, robust financial position and strategy ensure that our long-term prospects remain strong."

- ENDS -

For further information:

Rupert Pittman

Group Director of Corporate Affairs,

Chemring Group PLC

+44 (0)1794 833901

Andrew Jaques

Oliver Hughes

MHP Communications

+44 (0)20 3128 8100

Cautionary statement

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations. 

Notes to editors

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,500 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Countermeasures & Energetics, and Sensors & Information

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development, Chemring has the agility to rapidly react to urgent customer needs

www.chemring.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSFFFLDESSESL
Date   Source Headline
17th May 20167:00 amRNSDirectorate Change
10th May 20164:20 pmRNSDirector/PDMR Shareholding
5th May 20167:00 amRNSCompletion of Acquisition
3rd May 201610:08 amRNSTotal Voting Rights
27th Apr 20162:13 pmRNSDirectorate Change
25th Apr 20169:52 amRNSDirector/PDMR Shareholding
19th Apr 20167:00 amRNSAPPOINTMENT OF CHAIRMAN-DESIGNATE
6th Apr 20164:15 pmRNSDirector/PDMR Shareholding
4th Apr 20167:00 amRNSContract Update
1st Apr 20169:48 amRNSTotal Voting Rights
24th Mar 201610:36 amRNSHolding(s) in Company
21st Mar 20162:05 pmRNSResult of AGM
21st Mar 201611:00 amRNSAGM Trading Update
8th Mar 20162:36 pmRNSDirector/PDMR Shareholding
7th Mar 20167:00 amRNSAPPOINTMENT OF NON-EXECUTIVE DIRECTOR
1st Mar 20165:26 pmRNSCorrection Re Holding in Company
1st Mar 20161:24 pmRNSTotal Voting Rights
26th Feb 201610:23 amRNSHolding(s) in Company
24th Feb 20168:48 amRNSResult of Rump Placing
23rd Feb 20163:03 pmRNSResults of Rights Issue
23rd Feb 201612:40 pmRNSHolding(s) in Company
19th Feb 20163:13 pmRNSDirector/PDMR Shareholding
9th Feb 20168:07 amRNSAdmission of Nil Paid Rights
8th Feb 201611:52 amRNSResult of EGM
4th Feb 201611:26 amRNSDirector/PDMR Shareholding
4th Feb 201611:25 amRNSDirector/PDMR Shareholding
1st Feb 201611:18 amRNSTotal Voting Rights
27th Jan 20167:00 amRNSDirector/PDMR Shareholding
21st Jan 20163:30 pmRNSPublication of Prospectus
21st Jan 20167:00 amRNS£80.8 million Rights Issue
21st Jan 20167:00 amRNSFinal Results
20th Jan 20164:01 pmRNSDirector/PDMR Shareholding
4th Jan 201610:01 amRNSTotal Voting Rights
21st Dec 201511:19 amRNSBlocklisting Update
21st Dec 201511:17 amRNSBlocklisting Interim Review
1st Dec 20159:57 amRNSTotal Voting Rights
25th Nov 20157:00 amRNSPOST-CLOSE STATEMENT
2nd Nov 201511:21 amRNSHolding(s) in Company
27th Oct 20157:00 amRNSTrading Statement
1st Oct 201511:15 amRNSTotal Voting Rights
29th Sep 20152:25 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSTrading Update
1st Sep 20159:33 amRNSTotal Voting Rights
20th Aug 20153:01 pmRNSHolding(s) in Company
7th Aug 20151:56 pmRNSHolding(s) in Company
3rd Aug 20159:28 amRNSTotal Voting Rights
1st Jul 20152:47 pmRNSTotal Voting Rights
24th Jun 20155:26 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHalf Yearly Report
19th Jun 20158:55 amRNSBlocklisting Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.